Avicanna Closes C$1.6m in Seed Funding

Avicanna Inc., a Toronto, Canada-based biotechnology company focused on innovative approaches and technologies in the medical cannabis sector, completed its C$1.6m seed financing.

The company intends to use the funds for the clinical development of its primary product line “PURA Elements”.

Led by Aras Azadian, CEO, Avicanna is a biotechnology company focused on innovative and technological advancements in the medical cannabis industry. The company’s current leading product line includes the PURA Elements brand, which consists of several advanced cannabinoid delivery mechanisms including THC- and CBD-based transdermal patches.
Avicanna has also been accepted into Johnson & Johnson Innovation, JLABS @ Toronto, located in the MaRS Discovery District building, a centre of innovation in Toronto, Canada.



Join the discussion